Press Releases April 19, 2026 08:00 PM

Fiserv to Release First Quarter Earnings Results on May 5, 2026 and Confirms Details for May 14, 2026 Investor Day

Fiserv announces Q1 2026 earnings release and details for upcoming Investor Day in May.

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
FISV

Fiserv, Inc. will release its first quarter 2026 earnings results on May 5 before market open, followed by a webcast presentation. Furthermore, the company will hold an Investor Day on May 14 to detail its business strategy and medium-term outlook. Both events will be accessible via live webcast on the company's investor relations website.

Fiserv to Release First Quarter Earnings Results on May 5, 2026 and Confirms Details for May 14, 2026 Investor Day
FISV
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Fiserv will announce Q1 2026 earnings on May 5, 2026, with a live webcast presentation.
  • Investor Day scheduled for May 14, 2026, to present company strategy and outlook.
  • Fiserv is a leader in payments and financial technology, impacting fintech and financial services sectors.

MILWAUKEE, April 20, 2026 (GLOBE NEWSWIRE) -- Fiserv, Inc. (NASDAQ: FISV), a leading global provider of payments and financial services technology solutions, will announce its first quarter financial results before the market opens on Tuesday, May 5, 2026. The company will discuss its results in a live webcast at 7 a.m. CT (8 a.m. ET) on May 5, 2026. The webcast, along with supplemental financial information, can be accessed on the investor relations section of the Fiserv website at investors.fiserv.com. A replay will be available approximately one hour after the conclusion of the live webcast.

Additionally, Fiserv will host its previously announced 2026 Investor Day on Thursday, May 14, 2026, in New York City. The Investor Day will cover additional details of the company's business strategy, medium-term outlook, and presentations from its leadership team responsible for executing the strategy. The program will also be available through a live webcast beginning at 8 a.m. CT (9 a.m. ET) on May 14, 2026. The webcast can be accessed on the investor relations section of the Fiserv website at investors.fiserv.com.

About Fiserv

Fiserv, Inc. (NASDAQ: FISV), a Fortune 500 company, moves more than money. As a global leader in payments and financial technology, the company helps clients achieve best-in-class results through a commitment to innovation and excellence in areas including account processing and digital banking solutions; card issuer processing and network services; payments; e-commerce; merchant acquiring and processing; and Clover®, the world’s smartest point-of-sale system and business management platform. Fiserv is a member of the S&P 500® Index and one of TIME Magazine’s Most Influential Companies™. Visit fiserv.com and follow on social media for more information and the latest company news.

For more information contact:

Media Relations:
Melissa Moritz
Vice President, External Communications
Fiserv, Inc.
+1 516-410-1188
[email protected]Investor Relations:
Walter Pritchard
Senior Vice President, Investor Relations
Fiserv, Inc.
[email protected]

Risks

  • Market reactions to earnings results can be volatile depending on performance versus expectations.
  • Execution risk related to the company's business strategy presented during Investor Day.
  • Broader fintech and economic conditions could impact Fiserv's financial performance and stock price.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026